ARTICLE | Company News
DynPort, ID Biomedical deal
January 20, 2003 8:00 AM UTC
IDBE received a $6 million subcontract from DynPort to clone, express and produce antigen for use in DynPort's second-generation subunit recombinant vaccine for Yersinia pestis bacteria infection (the...